SNGX · Soligenix, Inc. · Investor Relations
$0.35
+0.01 (+3.17%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“However, as of the date of this filing, the Company continues to explore various strategic alternatives but has not consummated any transaction or obtained any additional program assets to develop which raises substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 7, 2026
Market Cap
$7.48M
Shares
21.77M
Volume · Oct 20
81.15K
Avg daily vol (3M)
222.33K
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Past events
| Date | Event | Type |
|---|---|---|
| 2021-01-26 | U.S. Commercialization of SGX301 in the Treatment of Cutaneous T-Cell Lymphoma | Webcast |
| 2020-12-22 | Phase 3 OM Results | Event |
| 2020-09-10 | CiVax™ Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine | Webcast |
| 2020-03-19 | Positive Phase 3 CTCL Results | Event |
Source: https://ir.soligenix.com/